Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells

15 Sept 2020

Abstract excerpt

The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as they simultaneously target different classes of CDKs - enzymes controlling the cell cycle progression as well as CDKs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Degradation and Inhibitors
Share to Cancer-related Molecular Pathways
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32934219
DOI: 10.1038/s41419-020-02971-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cellsPMID 32934219Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitorSemantic proximity Read ↗

Overview of CDK9 as a target in cancer researchSemantic proximity Read ↗

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

CDK9: A key player in cancer and other diseasesSemantic proximity Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read ↗

CDK4 inhibition diminishes p53 activation by MDM2 antagonistsSemantic proximity Read ↗

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug TargetSemantic proximity Read ↗

Cyclin-Dependent Kinase Inhibitors as Anticancer DrugsSemantic proximity Read ↗

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.